Compass Therapeutics, Inc. $CMPX Shares Acquired by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP increased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 65.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 940,538 shares of the company’s stock after purchasing an additional 371,791 shares during the quarter. Compass Therapeutics accounts for about 1.6% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 18th largest holding. Seven Fleet Capital Management LP owned about 0.52% of Compass Therapeutics worth $4,975,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in CMPX. DV Trading LLC increased its stake in Compass Therapeutics by 1,649.8% during the first quarter. DV Trading LLC now owns 423,566 shares of the company’s stock valued at $2,241,000 after purchasing an additional 399,359 shares during the last quarter. Parallel Advisors LLC acquired a new stake in shares of Compass Therapeutics during the first quarter worth $28,000. Bank of America Corp DE lifted its position in shares of Compass Therapeutics by 224.9% in the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock worth $4,579,000 after buying an additional 599,179 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Compass Therapeutics in the 1st quarter worth about $294,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Compass Therapeutics by 1,294.2% in the 1st quarter. California State Teachers Retirement System now owns 112,316 shares of the company’s stock valued at $594,000 after buying an additional 104,260 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CMPX shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 28th. Wall Street Zen cut shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a research note on Monday, June 1st. LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $5.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $12.25.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $1.91 on Friday. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88. The stock’s fifty day moving average is $2.12 and its 200-day moving average is $3.99. The firm has a market capitalization of $343.97 million, a price-to-earnings ratio of -4.66 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Analysts forecast that Compass Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.